MELBOURNE-BASED Telix Pharmaceuticals has filed a registration statement with the US Securities and Exchange Commission with a view to list on the Nasdaq Stock Market.
The company said a listing would facilitate further growth among US and global investors but that it was not planning to issue any new shares.
Telix said its US operation was expanding through organic growth and acquisitions, with most employees now US-based.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Oct 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Oct 24
